Ad
related to: treatment of monoclonal gammopathy- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Official Physician Site
Visit Site For A Treatment
Option For Metastatic Solid Tumors.
- Mechanism Of Action
MOA For A Therapy In Multiple
Metastatic Solid Tumor Types.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Monoclonal gammopathy, also known as paraproteinemia, is the presence of excessive amounts of myeloma protein or monoclonal gamma globulin in the blood. It is usually due to an underlying immunoproliferative disorder or hematologic neoplasms, especially multiple myeloma. It is sometimes considered equivalent to plasma cell dyscrasia.
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma cells or other types of antibody-producing cells secrete a myeloma protein, i.e. an abnormal antibody, into the blood; this abnormal protein is usually found during standard laboratory blood or urine tests.
Treatment is directed at the underlying monoclonal gammopathy, [11] and is intended to reduce the production of the monoclonal proteins [12] and may include bortezomib-based treatment, an autologous stem cell transplant, and if the patient is considered eligible, an organ transplant. [2]
Serum protein electrophoresis showing a paraprotein (spike/peak in the gamma zone) in a patient with multiple myeloma.. A myeloma protein is an abnormal antibody (immunoglobulin) or (more often) a fragment thereof, such as an immunoglobulin light chain, that is produced in excess by an abnormal monoclonal proliferation of plasma cells, typically in multiple myeloma or Monoclonal gammopathy of ...
The optimal treatment in MGRS is a clone directed therapy; where treatment is directed specifically to the cell line responsible for the pathologic monoclonal immunoglobulin or M-protein. [3] The goal of therapy is to preserve kidney function, reduce the risk of MGRS recurrence after kidney transplant and maintain a sustained hematologic response.
In hematology, plasma cell dyscrasias (also termed plasma cell disorders and plasma cell proliferative diseases) are a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant plasma cells (sometimes in association with lymphoplasmacytoid cells or B lymphocytes) over-produce and secrete into the blood stream a myeloma ...
A disease of gamma globulins is called a "gammopathy" (for example, in monoclonal gammopathy of undetermined significance). Brutton's agammaglobulinemia is an X-linked recessive disorder characterized by recurrent infections in the early-post natal period attributable to failure of pre-B cells to mature.
[1] [4] Even if patients do not have a monoclonal gammopathy before a diagnosis of crystal-storing histiocytosis, they are often tested to see if there is an underlying monoclonal gammopathy, due to the link between the disorders. [1] Patients who do not have a monoclonal gammopathy at diagnosis should be regularly tested to detect if one ...